Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 9, 2010

Primary Completion Date

October 15, 2011

Study Completion Date

October 15, 2011

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Brodalumab

Administered as as an intravenous (IV) infusion over at least 30 minutes.

DRUG

Placebo

Administered as as an intravenous (IV) infusion over at least 30 minutes.

Trial Locations (50)

Unknown

Research Site, Birmingham

Research Site, Dothan

Research Site, Lowell

Research Site, Jacksonville

Research Site, Miami

Research Site, Hammond

Research Site, Chevy Chase

Research Site, Rochester

Research Site, Mexico

Research Site, Egg Harbor

Research Site, Great Neck

Research Site, Charlotte

Research Site, Wilmington

Research Site, Germantown

Research Site, Nashville

Research Site, San Antonio

Research Site, Logan

Research Site, Ogden

Research Site, Kurralta Park

Research Site, Box Hill

Research Site, Fitzroy

Research Site, Fremantle

Research Site, Bonheiden

Research Site, Ghent

Research Site, Leuven

Research Site, Roeselare

Research Site, Calgary

Research Site, Vancouver

Research Site, Victoria

Research Site, Winnipeg

Research Site, Hamilton

Research Site, London

Research Site, Toronto

Research Site, Montreal

Research Site, Lille

Research Site, Nice

Research Site, Paris

Research Site, Toulouse

Research Site, Vandœuvre-lès-Nancy

Research Site, Amsterdam

Research Site, Maastricht

Research Site, Rotterdam

Research Site, Bydgoszcz

Research Site, Olsztyn

Research Site, Opole

Research Site, Sopot

Research Site, Pontevedra

Research Site, Santiago de Compostela

Research Site, Barcelona

Research Site, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY